ATE478889T1 - Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease - Google Patents

Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease

Info

Publication number
ATE478889T1
ATE478889T1 AT08102711T AT08102711T ATE478889T1 AT E478889 T1 ATE478889 T1 AT E478889T1 AT 08102711 T AT08102711 T AT 08102711T AT 08102711 T AT08102711 T AT 08102711T AT E478889 T1 ATE478889 T1 AT E478889T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
inhibitors
novel compounds
serine protease
Prior art date
Application number
AT08102711T
Other languages
English (en)
Inventor
Ashok Arasappan
F George Njoroge
Angela I Padilla-Acevedo
Kevin X Chen
Frank Bennet
Mousumi Sannigrahi
Stephane L Bogen
Srikanth Venkatraman
Edwin Jao
Anil K Saksena
Viyyoor Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE478889T1 publication Critical patent/ATE478889T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08102711T 2004-02-27 2005-02-24 Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease ATE478889T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54853504P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ATE478889T1 true ATE478889T1 (de) 2010-09-15

Family

ID=34962125

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05723590T ATE434621T1 (de) 2004-02-27 2005-02-24 Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
AT08102711T ATE478889T1 (de) 2004-02-27 2005-02-24 Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05723590T ATE434621T1 (de) 2004-02-27 2005-02-24 Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus

Country Status (19)

Country Link
US (2) US7186747B2 (de)
EP (2) EP1939213B1 (de)
JP (1) JP2007525511A (de)
KR (1) KR20060124729A (de)
CN (1) CN1972956A (de)
AR (1) AR047903A1 (de)
AT (2) ATE434621T1 (de)
AU (1) AU2005222056A1 (de)
BR (1) BRPI0508186A (de)
CA (1) CA2557249A1 (de)
DE (2) DE602005023224D1 (de)
EC (1) ECSP066794A (de)
ES (2) ES2327544T3 (de)
IL (1) IL177627A0 (de)
NO (1) NO20064357L (de)
RU (1) RU2006134002A (de)
TW (1) TW200529823A (de)
WO (1) WO2005087725A2 (de)
ZA (1) ZA200607053B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
CN101212970B (zh) * 2005-06-02 2010-07-21 先灵公司 Hcv蛋白酶抑制剂与表面活性剂的组合物
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
NZ563369A (en) * 2005-06-02 2011-03-31 Schering Corp Controlled-release formulation useful for treating disorders associated with hepatitus C virus
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
WO2006130554A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
WO2006130687A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
AU2006315438A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7990344B2 (en) 2006-02-14 2011-08-02 Panasonic Corporation Plasma display panel driving method having a high temperature and low temperature driving mode and plasma display device thereof
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
JP2010500978A (ja) 2006-08-17 2010-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
US20100204159A1 (en) * 2006-09-13 2010-08-12 Trixl Brandl Organic compounds and their uses
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
KR20100024920A (ko) * 2007-05-03 2010-03-08 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
MX2009012093A (es) * 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
EP2188274A4 (de) 2007-08-03 2011-05-25 Boehringer Ingelheim Int Virale polymerasehemmer
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2010080874A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EP2545060B1 (de) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Kondensierte tricyclische silylverbindngen und verfahren zu deren verwendung zur behandlung von viralen krankheiten
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (de) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Kondensierte tetrazyklische derivate und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2696681B1 (de) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituierte nukleosidderivate und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
ES2553449T3 (es) * 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
TW202138365A (zh) 2016-08-19 2021-10-16 美商基利科學股份有限公司 治療性化合物
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN111836805B (zh) 2018-02-15 2023-07-14 吉利德科学公司 吡啶衍生物及其用于治疗hiv感染的用途
TWI745652B (zh) 2018-02-16 2021-11-11 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
EP4643882A3 (de) 2019-11-26 2026-01-14 Gilead Sciences, Inc. Capsid-inhibitoren zur prävention von hiv
JP7520162B2 (ja) 2020-06-25 2024-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの治療のためのカプシド阻害剤
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
PT4440702T (pt) 2021-12-03 2025-08-13 Gilead Sciences Inc Compostos terapêuticos para a infecção pelo vírus do hiv
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
CN114133350B (zh) * 2021-12-16 2023-05-23 浙江乐普药业股份有限公司 一种抗新冠药物Paxlovid中间体的制备方法
WO2023151188A1 (zh) * 2022-02-08 2023-08-17 上海皓元医药股份有限公司 一种抗病毒药物中间体的绿色合成方法
CN116835730B (zh) * 2023-06-15 2025-09-02 江南大学 一种用于抑制有害藻生长的双功能抑藻剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8807310A (pt) 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
ATE132182T1 (de) 1989-02-01 1996-01-15 Asahi Glass Co Ltd Azeotrope oder azeotropähnliche zusammensetzung auf der basis von chlorfluorkohlenwasserstoffen
DE69133617D1 (de) 1990-04-04 2009-07-23 Novartis Vaccines & Diagnostic Protease von Hepatitis C Virus
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP1012180B1 (de) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP4806154B2 (ja) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
JP4748911B2 (ja) 2000-04-05 2011-08-17 シェーリング コーポレイション Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
NZ521456A (en) 2000-04-19 2004-07-30 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
WO2002008187A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
MXPA03000627A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
CA2418199A1 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
HUP0303436A2 (hu) 2000-12-12 2004-01-28 Schering Corp. Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2002349498A (ja) * 2001-05-24 2002-12-04 Ishikawajima Harima Heavy Ind Co Ltd 低騒音ファン静翼

Also Published As

Publication number Publication date
AR047903A1 (es) 2006-03-01
JP2007525511A (ja) 2007-09-06
WO2005087725A3 (en) 2005-10-27
EP1737881A2 (de) 2007-01-03
CA2557249A1 (en) 2005-09-22
DE602005015093D1 (de) 2009-08-06
HK1118066A1 (en) 2009-01-30
HK1095837A1 (en) 2007-05-18
NO20064357L (no) 2006-11-24
ES2327544T3 (es) 2009-10-30
EP1737881B1 (de) 2009-06-24
US7186747B2 (en) 2007-03-06
US20050245458A1 (en) 2005-11-03
ZA200607053B (en) 2009-02-25
US7425576B2 (en) 2008-09-16
WO2005087725A2 (en) 2005-09-22
RU2006134002A (ru) 2008-04-10
DE602005023224D1 (de) 2010-10-07
BRPI0508186A (pt) 2007-08-14
TW200529823A (en) 2005-09-16
KR20060124729A (ko) 2006-12-05
ECSP066794A (es) 2006-11-16
ATE434621T1 (de) 2009-07-15
EP1939213A1 (de) 2008-07-02
CN1972956A (zh) 2007-05-30
EP1939213B1 (de) 2010-08-25
AU2005222056A1 (en) 2005-09-22
ES2349328T3 (es) 2010-12-30
US20070142300A1 (en) 2007-06-21
IL177627A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
DE602005023224D1 (de) Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
DE602005021760D1 (de) Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE602005015452D1 (de) Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
ATE438622T1 (de) 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
IL177545A0 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
ATE490265T1 (de) Schwefelverbindungen als hemmer der ns3-serin- protease des hepatitis-c-virus
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
ATE497505T1 (de) Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
ATE514691T1 (de) Neue ketoamide mit cyclischen p4 als inhibitoren der ns3-serinprotease von hepatitis-c-virus
DE60332814D1 (de) Peptide als hemmer der serinprotease des hepatitis c virus
ATE378334T1 (de) Verbindungen als hepatitis c inhibitoren
ZA200607134B (en) Inhibitors of hepatitis C virus NS3 protease
DK1385870T3 (da) Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
ATE494288T1 (de) Makrozyklische hemmer des hepatitis-c-virus
EA201170241A1 (ru) Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3
ATE323081T1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
HK1097528A (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
AU2009225346B2 (en) Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease
HK1097262A (en) Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
HK1097261A (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
HK1103408A (en) Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
DK1268519T3 (da) Inhibitorer af serinproteaser, især hepatitis C-virus NS3-protease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties